Single center experience in patients with a diagnosis of nodular lymphocyte predominant Hodgkin lymphoma

Year 2021, Volume: 3 Issue: Supplement 1, 40 - 41, 07.03.2021

Ömer Candar , Fahir Özkalemkaş , Vildan Ozkocaman , Tuba Ersal İbrahim Ethem Pınar , Cumali Yalçın Bedrettin Orhan

https://doi.org/10.46310/tjim.877049

Abstract

Nodular lymphocyte predominant Hodgkin lymphoma is an infrequent disease. It is associated with a favorable prognosis. The most important problems with the management of the disease are relapses, transformation to non-Hodgkin lymphoma, and treatment-related toxicities. In early stages of disease, watchful waiting, surgery, radiotherapy, and single-agent rituximab are the treatment options. Chemo-immunotherapy may be preferred in early disease with high tumor and symptom burden. In advanced disease, chemo-immunotherapy with or without radiotherapy is used. Good responses can be achieved in relapsed disease. The risk of transformation is high. It is reasonable to obtain re-biopsies at relapses. Transformed disease and the primary disease have been shown to be clonally-related in most cases. Prognosis of transformed disease which is treated with salvage chemo-immunotherapy followed by autologous stem cell transplantation is similar to that of de novo diffuse large B-cell lymphoma. All of the data regarding the treatment come from retrospective data.

Keywords

Nodular lymphocyte predominant Hodgkin lymphoma, Hodgkin lymphoma, prognosis

References

• Spinner MA, Varma G, Advani RH. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2019 Jan;184(1):17-29. doi: 10.1111/bjh.15616. Epub 2018 Nov 28. PMID: 30485408.
• Hartmann S, Eichenauer DA. Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma. Pathology. 2020 Jan;52(1):142-153. doi: 10.1016/j.pathol.2019.10.003. Epub 2019 Nov 28. PMID: 31785822.
• Borchmann S, Joffe E, Moskowitz CH, Zelenetz AD, Noy A, Portlock CS, Gerecitano JF, Batlevi CL, Caron PC, Drullinsky P, Hamilton A, Hamlin PA Jr, Horwitz SM, Kumar A, Matasar MJ, Moskowitz AJ, Owens CN, Palomba ML, Younes A, Straus DJ. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2019 May 16;133(20):2121-2129. doi: 10.1182/blood-2018-10-877761. Epub 2019 Feb 15. PMID: 30770396; PMCID: PMC7022227.